Derived From Cannabis, Pt. 3 Cannabichromene (CBC)

January 28, 2013


“There has been for many years an ongoing search for the discovery and development of more effective anti-inflammatory and hypothermia inducing agents which can be administered to mammals in therapeutically effective dosages with minimal side effects. There is also an economic need for such agents which are relatively simple to produce from readily available non-costly reagents.”


This is a description for the background of the invention of US Patent 4315862 for preparing cannabichromene. Cannabichromene is another cannaboid that the government has patented, but won’t allow us to use, even for medical purposes.  Despite the fact the government is obiviously aware that we need a substance that can do what it does therapeutically and at the low cost of cannabis.

Cannabichromene (CBC) was first discovered in 1966. It is typically found in significant quantities in freshly harvested, dry cannabis. To date, the compound has not been subject to rigorous study; fewer than 75 published papers available on PubMed make specific reference to CBC. According to a 2009 review of cannabichromine and other non-psychotropic cannabinoids, “CBC exerts anti-inflammatory, antimicrobial, and modest analgesic activity.” CBC has also been shown to promote anti-cancer activity in malignant cell lines and to possess bone-stimulating properties. More recently, a 2011 preclinical trial reported that CBC influences nerve endings above the spine to modify sensations of pain. “[This] compound might represent [a] useful therapeutic agent with multiple mechanisms of action,” the study concluded.